Stephen J Polyak

List of Publications by Year
in descending order

81 papers	5,452 citations	76294 40 h-index	82499 72 g-index
94 all docs	94 docs citations	94 times ranked	7131 citing authors

#	Article	IF	Citations
1	Response of Human Liver Tissue to Innate Immune Stimuli. Frontiers in Immunology, 2022, 13, 811551.	2.2	1
2	Mono- and combinational drug therapies for global viral pandemic preparedness. IScience, 2022, 25, 104112.	1.9	19
3	Human Immunodeficiency Virus Is Associated With Higher Levels of Systemic Inflammation Among Kenyan Adults Despite Viral Suppression. Clinical Infectious Diseases, 2021, 73, e2034-e2042.	2.9	10
4	Targeting clinical epigenetic reprogramming for chemoprevention of metabolic and viral hepatocellular carcinoma. Gut, 2021, 70, 157-169.	6.1	57
5	CRISPR-Cas9 gene editing of hepatitis B virus in chronically infected humanized mice. Molecular Therapy - Methods and Clinical Development, 2021, 20, 258-275.	1.8	62
6	Inhibition of Arenaviruses by Combinations of Orally Available Approved Drugs. Antimicrobial Agents and Chemotherapy, 2021, 65, .	1.4	27
7	Artemisia annua L. extracts inhibit the in vitro replication of SARS-CoV-2 and two of its variants. Journal of Ethnopharmacology, 2021, 274, 114016.	2.0	80
8	Central obesity is a contributor to systemic inflammation and monocyte activation in virally suppressed adults with chronic HIV in Kenya. Aids, 2021, 35, 1723-1731.	1.0	3
9	Liver Abnormalities after Elimination of HCV Infection: Persistent Epigenetic and Immunological Perturbations Post-Cure. Pathogens, 2021, 10, 44.	1.2	11
10	Antiretroviral therapy reduces but does not normalize immune and vascular inflammatory markers in adults with chronic HIV infection in Kenya. Aids, 2021, 35, 45-51.	1.0	10
11	Drug Combinations as a First Line of Defense against Coronaviruses and Other Emerging Viruses. MBio, 2021, 12, e0334721.	1.8	45
12	Evaluation of the potential of botanicals and their constituents against the SARS-CoV-2 virus. Planta Medica, 2021, 87, .	0.7	0
13	Endothelial Dysfunction Is Related to Monocyte Activation in Antiretroviral-Treated People With HIV and HIV-Negative Adults in Kenya. Open Forum Infectious Diseases, 2020, 7, ofaa425.	0.4	13
14	Postpartum metabolic syndrome and highâ€sensitivity Câ€reactive protein after gestational hypertension and preâ€eclampsia. International Journal of Gynecology and Obstetrics, 2020, 151, 443-449.	1.0	6
15	Metabolic syndrome and 10-year cardiovascular risk among HIV-positive and HIV-negative adults. Medicine (United States), 2020, 99, e20845.	0.4	21
16	Mechanisms of Endogenous HIV-1 Reactivation by Endocervical Epithelial Cells. Journal of Virology, 2020, 94, .	1.5	9
17	Postpartum metabolic syndrome after gestational hypertension and preeclampsia, a prospective cohort study. Pregnancy Hypertension, 2019, 18, 35-41.	0.6	11
18	The broad-spectrum antiviral drug arbidol inhibits foot-and-mouth disease virus genome replication. Journal of General Virology, 2019, 100, 1293-1302.	1.3	22

#	Article	IF	Citations
19	The broad-spectrum antiviral drug arbidol inhibits foot-and-mouth disease virus replication. Access Microbiology, 2019, 1, .	0.2	0
20	1,4-Benzodioxane Lignans: An Efficient, Asymmetric Synthesis of Flavonolignans and Study of Neolignan Cytotoxicity and Antiviral Profiles. Journal of Natural Products, 2018, 81, 2630-2637.	1.5	14
21	The Antiviral Drug Arbidol Inhibits Zika Virus. Scientific Reports, 2018, 8, 8989.	1.6	77
22	Chemoselective fluorination and chemoinformatic analysis of griseofulvin: Natural vs fluorinated fungal metabolites. Bioorganic and Medicinal Chemistry, 2017, 25, 5238-5246.	1.4	18
23	Silymarin suppresses basal and stimulus-induced activation, exhaustion, differentiation, and inflammatory markers in primary human immune cells. PLoS ONE, 2017, 12, e0171139.	1.1	15
24	The Synthetic Antiviral Drug Arbidol Inhibits Globally Prevalent Pathogenic Viruses. Journal of Virology, 2016, 90, 3086-3092.	1.5	133
25	A validated UHPLC-tandem mass spectrometry method for quantitative analysis of flavonolignans in milk thistle (Silybum marianum) extracts. Journal of Pharmaceutical and Biomedical Analysis, 2016, 126, 26-33.	1.4	29
26	Uncovering biologically significant lipid isomers with liquid chromatography, ion mobility spectrometry and mass spectrometry. Analyst, The, 2016, 141, 1649-1659.	1.7	196
27	Natural Products as Tools for Defining How Cellular Metabolism Influences Cellular Immune and Inflammatory Function during Chronic Infection. Viruses, 2015, 7, 6218-6232.	1.5	20
28	Enantioselective Synthesis, Stereochemical Correction, and Biological Investigation of the Rodgersinine Family of 1,4-Benzodioxane Neolignans. Organic Letters, 2015, 17, 1046-1049.	2.4	21
29	Silymarin Suppresses Cellular Inflammation By Inducing Reparative Stress Signaling. Journal of Natural Products, 2015, 78, 1990-2000.	1.5	53
30	Human Cytokinome Analysis for Interferon Response. Journal of Virology, 2015, 89, 7108-7119.	1.5	14
31	Hepatitis C Virus Core Protein Inhibits Interferon Production by a Human Plasmacytoid Dendritic Cell Line and Dysregulates Interferon Regulatory Factor-7 and Signal Transducer and Activator of Transcription (STAT) 1 Protein Expression. PLoS ONE, 2014, 9, e95627.	1.1	23
32	Arbidol as a broad-spectrum antiviral: An update. Antiviral Research, 2014, 107, 84-94.	1.9	375
33	Direct, Interferon-Independent Activation of the CXCL10 Promoter by NF-Î¹B and Interferon Regulatory Factor 3 during Hepatitis C Virus Infection. Journal of Virology, 2014, 88, 1582-1590.	1.5	96
34	Inhibition of HIV by Legalon-SIL is independent of its effect on cellular metabolism. Virology, 2014, 449, 96-103.	1.1	11
35	Independent, parallel pathways to CXCL10 induction in HCV-infected hepatocytes. Journal of Hepatology, 2013, 59, 701-708.	1.8	33
36	Arbidol inhibits viral entry by interfering with clathrin-dependent trafficking. Antiviral Research, 2013, 100, 215-219.	1.9	72

#	Article	IF	Citations
37	Enhanced bioactivity of silybin B methylation products. Bioorganic and Medicinal Chemistry, 2013, 21, 742-747.	1.4	27
38	Molecular Pathways: Hepatitis C Virus, CXCL10, and the Inflammatory Road to Liver Cancer. Clinical Cancer Research, 2013, 19, 1347-1352.	3.2	56
39	Hepatoprotective and antiviral functions of silymarin components in hepatitis C virus infection. Hepatology, 2013, 57, 1262-1271.	3.6	103
40	Semisynthesis, cytotoxicity, antiviral activity, and drug interaction liability of 7-O-methylated analogues of flavonolignans from milk thistle. Bioorganic and Medicinal Chemistry, 2013, 21, 3919-3926.	1.4	20
41	Silibinin inhibits hepatitis C virus entry into hepatocytes by hindering clathrin-dependent trafficking. Cellular Microbiology, 2013, 15, n/a-n/a.	1.1	73
42	Analysis of hepatitis C virus resistance to silibinin in vitro and in vivo points to a novel mechanism involving nonstructural protein 4B. Hepatology, 2013, 57, 953-963.	3.6	44
43	The circulatory orbit of micro-RNAs in hepatitis C. Hepatology, 2013, 58, 847-849.	3.6	1
44	Silymarin for HCV infection. Antiviral Therapy, 2013, 18, 141-147.	0.6	55
45	In Vitro Toxicity Assessment of Amphiphillic Polymer-Coated CdSe/ZnS Quantum Dots in Two Human Liver Cell Models. ACS Nano, 2012, 6, 9475-9484.	7.3	58
46	Silibinin Inhibits HIV-1 Infection by Reducing Cellular Activation and Proliferation. PLoS ONE, 2012, 7, e41832.	1.1	30
47	Myeloid suppressor cells induced by hepatitis C virus suppress T-cell responses through the production of reactive oxygen species. Hepatology, 2012, 55, 343-353.	3.6	176
48	Naringenin inhibits the assembly and long-term production of infectious hepatitis C virus particles through a PPAR-mediated mechanism. Journal of Hepatology, 2011, 55, 963-971.	1.8	121
49	Differential In Vitro Effects of Intravenous versus Oral Formulations of Silibinin on the HCV Life Cycle and Inflammation. PLoS ONE, 2011, 6, e16464.	1.1	62
50	Multiple effects of silymarin on the hepatitis C virus lifecycle. Hepatology, 2010, 51, 1912-1921.	3.6	191
51	Hepatitis C virus induces oxidative stress, DNA damage and modulates the DNA repair enzyme NEIL1. Journal of Gastroenterology and Hepatology (Australia), 2010, 25, 627-634.	1.4	115
52	A Crucial Role for Kupffer Cell-Derived Galectin-9 in Regulation of T Cell Immunity in Hepatitis C Infection. PLoS ONE, 2010, 5, e9504.	1.1	161
53	Functional Characterization of Core Genes from Patients with Acute Hepatitis C Virus Infection. Journal of Infectious Diseases, 2010, 201, 912-922.	1.9	7
54	Identification of hepatoprotective flavonolignans from silymarin. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 5995-5999.	3.3	262

#	Article	IF	Citations
55	A versatile ribosomal protein promoter-based reporter system for selective assessment of RNA stability and post-transcriptional control. Rna, 2010, 16, 1245-1255.	1.6	27
56	Silymarin Inhibits In Vitro T-Cell Proliferation and Cytokine Production in Hepatitis C Virus Infection. Gastroenterology, 2010, 138, 671-681.e2.	0.6	107
57	Antiviral effects of silymarin against hepatitis C: The jury is still out. Hepatology, 2008, 48, 345-346.	3.6	5
58	Resistance of HBV and HCV to antiviral therapies. Future Virology, 2008, 3, 221-224.	0.9	0
59	Regulation of CXCL-8 (Interleukin-8) Induction by Double-Stranded RNA Signaling Pathways during Hepatitis C Virus Infection. Journal of Virology, 2007, 81, 309-318.	1.5	71
60	Biochemical Mechanism of Hepatitis C Virus Inhibition by the Broad-Spectrum Antiviral Arbidol. Biochemistry, 2007, 46, 6050-6059.	1.2	80
61	Inhibition of T-Cell Inflammatory Cytokines, Hepatocyte NF-ÎºB Signaling, and HCV Infection by Standardized Silymarin. Gastroenterology, 2007, 132, 1925-1936.	0.6	201
62	Engulfment of apoptotic cells expressing HCV proteins leads to differential chemokine expression and STAT signaling in human dendritic cells. Hepatology, 2007, 45, 1422-1432.	3.6	17
63	Arbidol: a broad-spectrum antiviral that inhibits acute and chronic HCV infection. Virology Journal, 2006, 3, 56.	1.4	77
64	Hepatitis C Virusâ€"Specific Immune Responses and Quasiâ€Species Variability at Baseline Are Associated with Nonresponse to Antiviral Therapy during Advanced Hepatitis C. Journal of Infectious Diseases, 2006, 193, 931-940.	1.9	55
65	Relationships between Hepatitis C Virus Replication and CXCL-8 Production In Vitro. Journal of Virology, 2006, 80, 7885-7893.	1.5	34
66	Stability of CXCLâ€8 and Related AUâ€Rich mRNAs in the Context of Hepatitis C Virus Replication In Vitro. Journal of Infectious Diseases, 2006, 193, 802-811.	1.9	19
67	Effect of ethanol on innate antiviral pathways and HCV replication in human liver cells. Virology Journal, 2005, 2, 89.	1.4	51
68	Comparison of amplification enzymes for Hepatitis C Virus quasispecies analysis. Virology Journal, 2005, 2, 41.	1.4	9
69	Unique Features of Hepatitis C Virus Capsid Formation Revealed by De Novo Cell-Free Assembly. Journal of Virology, 2004, 78, 9257-9269.	1.5	65
70	Effects of the Hepatitis C Virus Core Protein on Innate Cellular Defense Pathways. Journal of Interferon and Cytokine Research, 2004, 24, 391-402.	0.5	41
71	Expressed Gene Clusters Associated with Cellular Sensitivity and Resistance Towards Anti-viral and Anti-proliferative Actions of Interferon. Journal of Molecular Biology, 2004, 342, 833-846.	2.0	35
72	Hepatitis C virusâ€"cell interactions and their role in pathogenesis. Clinics in Liver Disease, 2003, 7, 67-88.	1.0	25

#	Article	IF	Citations
73	Detection of Hepatitis C Virus RNA in Normal Cervical Smears. Clinical Infectious Diseases, 2003, 37, 314-314.	2.9	2
74	Subversion of Cell Signaling Pathways by Hepatitis C Virus Nonstructural 5A Protein via Interaction with Grb2 and P85 Phosphatidylinositol 3-Kinase. Journal of Virology, 2002, 76, 9207-9217.	1.5	155
75	Hepatitis C Virus-Host Interactions: The NS5A Protein and the Interferon/Chemokine Systems. Journal of Interferon and Cytokine Research, 2002, 22, 1005-1012.	0.5	20
76	Hepatitis C Virus NS5A Colocalizes with the Core Protein on Lipid Droplets and Interacts with Apolipoproteins. Virology, 2002, 292, 198-210.	1.1	269
77	Analyzing the Mechanisms of Interferon-Induced Apoptosis Using CrmA and Hepatitis C Virus NS5A. Virology, 2001, 281, 124-137.	1.1	30
78	Elevated Levels of Interleukin-8 in Serum Are Associated with Hepatitis C Virus Infection and Resistance to Interferon Therapy. Journal of Virology, 2001, 75, 6209-6211.	1.5	219
79	Hepatitis C Virus Nonstructural 5A Protein Induces Interleukin-8, Leading to Partial Inhibition of the Interferon-Induced Antiviral Response. Journal of Virology, 2001, 75, 6095-6106.	1.5	285
80	Prospective Multicenter Clinical Evaluation of AMPLICOR and COBAS AMPLICOR Hepatitis C Virus Tests. Journal of Clinical Microbiology, 2001, 39, 4005-4012.	1.8	49
81	Characterization of the effects of hepatitis C virus nonstructural 5A protein expression in human cell lines and on interferon-sensitive virus replication. Hepatology, 1999, 29, 1262-1271.	3.6	140